Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report)’s stock price hit a new 52-week low on Thursday . The company traded as low as $18.86 and last traded at $18.88, with a volume of 55579 shares traded. The stock had previously closed at $19.18.
Fulgent Genetics Trading Up 1.4 %
The stock has a market cap of $581.12 million, a price-to-earnings ratio of -3.49 and a beta of 1.50. The stock’s 50 day moving average is $21.44 and its two-hundred day moving average is $21.41.
Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last released its earnings results on Friday, August 2nd. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The company had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. During the same quarter last year, the business earned ($0.33) EPS. The business’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts predict that Fulgent Genetics, Inc. will post -1.46 EPS for the current year.
Insider Transactions at Fulgent Genetics
Institutional Trading of Fulgent Genetics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Asset Dedication LLC acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $33,000. nVerses Capital LLC acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $43,000. Signaturefd LLC lifted its stake in shares of Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $63,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Fulgent Genetics in the first quarter valued at about $178,000. Institutional investors and hedge funds own 48.06% of the company’s stock.
About Fulgent Genetics
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Read More
- Five stocks we like better than Fulgent Genetics
- Compound Interest and Why It Matters When Investing
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Using the MarketBeat Dividend Tax Calculator
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 5 discounted opportunities for dividend growth investors
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.